Development, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patients

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Acharya, Arpan ^a   Vaniawala, Salil ^b   Shah, Parth ^b   Misra, Rabindra Nath ^c   Wani, Minal ^a   Mukhopadhyaya, Pratap N ^b  

^a DR D Y PATIL BIOTECHNOLOGY AND BIOINFORMATICS INSTITUTE   (India)

^b Department of Molecular Diagnostics SN Genelab ^*  (India)

^c HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENETIC PROCEDURES; GENOTYPE; HIV 1 DRUG RESISTANCE GENOTYPING ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INDIAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; SENSITIVITY ANALYSIS; UNINDEXED SEQUENCE; VALIDATION PROCESS; VIRUS LOAD; ANTIVIRAL RESISTANCE; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; GENETICS; GENOTYPING TECHNIQUE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INDIA; ISOLATION AND PURIFICATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; PHYLOGENY; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 84924276340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105790     Document Type: Article

References (37)

1. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, et al. (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338(13): 853-860. (Pubitemid 28135961)
3. National AIDS Control Programme: Operational guidelines for ART services; July 2012. Available: http://www.naco.gov.in/NACO/Quick-Links/Publication/ Treatment-Care-Support/Operational-Technical-guidelines-and-policies/ Operational-guidelines-for-ART-services-/.
4. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
5. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, et al. (2008) World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir Ther 13(2): 49-57. (Pubitemid 352019089)
6. Mehta N, Trzmielina S, Nonyane BA, Eliot MN, Lin R, et al. (2009) Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR. PLoS ONE 4: e5819. doi:10.1371/journal.pone.0005819.
7. Greengrass V, Plate MM, Steele PM, Taqi R, van Rooijen L, et al. (2007) HIV monitoring in laboratories in resource limited areas. J Chin Clin Med 2: 469-480.
8. Bergeron M, Daneau G, Ding T, Sitoe NE, Westerman LE, et al. (2012) Correction: performance of the PointCare NOW System for CD4 counting in HIV patients based on five independent evaluations. PLoS ONE 7(9). doi:10.1371/annotation/71a6d947-c034-4749-a33d-97.
9. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, et al. (2011) Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 25: 807-812.
10. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13(2): 25-36. (Pubitemid 352019087)
11. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF (2008) The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13(2): 1-13. (Pubitemid 352019085)
12. Saravanan S, Vidya M, Balakrishnan P, Kumaraswamy N, Solomon SS, et al. (2009) Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods 159(2): 211-216.
13. Peeters M, Toure-Kane C, Nkengasong JN (2003) Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17: 2547-2560. (Pubitemid 38402333)
14. Parkin N, de Mendoza C, Schuurman R, Jennings C, Bremer J, et al. (2012) Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin Infect Dis 54(S4): S273-S279.
15. Aitken SC, Kliphuis A, Wallis CL, Chu ML, Fillekes Q, et al. (2012) Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J Clin Virol 54: 21-25.
16. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, et al. (2010) Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 163: 505-508.
17. Shen C, Craigo J, Ding M, Chen Y, Gupta P (2011) Origin and dynamics of HIV-1 subtype C infection in India. PLoS one 6(10): e25956. doi:10.1371/journal. pone.0025956.
18. Acharya A, Vaniawala S, Parekh H, Nagee A, Misra RN, et al. (2013) Distinct geographical clustering of HIV-1 and a signature amino acid at position 41 of the p24 unveiled by gag variability in India. Curr HIV Res 11(4): 295-303.
19. Kumarasamy N, Patel A, Pujari S (2011) Antiretroviral therapy in Indian setting: When & that to start with, when & what to switch to? Indian J Med Res 134: 787-800.
20. Liu TF, Shafer RW (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
21. WHO (2009) HIV drug resistance laboratory training package, 2009: HIV Genotyping Assay Validation. Available: http://www.who.int/hiv/pub/ drugresistance/lab-training/en/.
22. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21(1): 6-14.
23. Saitou N. and Nei M (1987) The neighbor-joining method: A new method for reconstructing phylogenetic trees. Molecular Biology and Evolution 4: 406-425.
24. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Molecular Biology and Evolution 28: 2731-2739.
25. Felsenstein J (1985) Confidence limits on phylogenies: An approach using the bootstrap. Evolution 39: 783-791.
26. Aitken SC, Bronze M, Wallis CL, Stuyver L, Steegen K, et al. (2013) A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol 51: 1757-1761.
27. Geretti AM (2007) Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr Opin Infect Dis 20: 22-32.
28. Aghokeng AF, Mpoudi-Ngole E, Chia JE, Edoul EM, Delaporte E, et al. (2011) High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J Clin Microbiol 49: 1635-1641.
29. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, et al. (2009) Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 47: 1238-1240.
30. Chaturbhuj DN, Nirmalkar AP, Paranjape RS, Tripathy SP (2014) Evaluation of a Cost Effective In-House Method for HIV-1 Drug Resistance Genotyping Using Plasma Samples. PLoS ONE 9(2): e87441. doi:10.1371/journal.-pone.0087441.
31. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, et al. (2011) Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings. PLoS ONE 6(11): e28184. doi:10.1371/journal.pone.0028184.
32. Neogi U, Bontell I, Shet A, De Costa A, Gupta S, et al. (2012) Molecular Epidemiology of HIV-1 Subtypes in India: Origin and Evolutionary History of the Predominant Subtype C. PLoS ONE 7(6): e39819. doi:10.1371/journal.-pone.0039819.
33. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS (2007) High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 23(10): 1303-1308. (Pubitemid 350014773)
34. Deshpande A, Jauvin V, Magnin N, Pinson P, Faure M, et al. (2007) Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing treatment failure: Resistance to ART. AIDS Res Hum Retroviruses 23(2): 335-340. (Pubitemid 46418349)
35. Sinha S, Shekhar RC, Ahmad HS, Kumar N, Samantaray JC, et al. (2012) Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population after Failure of the First Line Antiretroviral Therapy. Current HIV Research 10(6): 532-538.
36. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, et al. (2009) High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 49: 306-309.
37. Vidya M, Saravanan S, Uma S, Kumarasamy N, Solomon SS, et al. (2009) Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in South India. Antivir Ther 14: 1005-1009.